ストックスクリーナーアプリを入手
4.38
4.48%
-0.20
アフターアワーズ：
4.41
0.03
+0.68%
Vir Biotechnology Inc (VIR) 最新ニュース
Price Clustering Detected in Vir Biotechnology Inc. StockQuarterly Portfolio Summary & Real-Time Buy Signal Notifications - thegnnews.com
Published on: 2025-08-21 00:08:39 - kangso.co.kr
Sentiment Turns Positive on Vir Biotechnology Inc. — Reversal AheadJuly 2025 Price Swings & AI Optimized Trade Strategies - newsyoung.net
Sector Rotation Brings Vir Biotechnology Inc. Into FocusPortfolio Risk Summary & Weekly High Conviction Trade Ideas - kangso.co.kr
Can Vir Biotechnology Inc. recover in the next quarterMarket Movers & Free Real-Time Volume Trigger Notifications - Newser
Vir Biotechnology Inc. stock outlook for YEAR2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Vir Biotechnology Inc.’s volatility index tracking explained2025 Market Outlook & Long-Term Safe Return Strategies - Newser
How to integrate Vir Biotechnology Inc. into portfolio analysis tools2025 EndofYear Setup & Verified Momentum Stock Alerts - Newser
Predicting Vir Biotechnology Inc. trend using moving averagesJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - Newser
What to expect from Vir Biotechnology Inc. in the next 30 daysMarket Activity Summary & AI Driven Stock Price Forecasts - Newser
Vir Biotechnology Inc. Volume Confirms Breakout — Analysts Bullish2025 Retail Activity & Free Safe Entry Trade Signal Reports - 선데이타임즈
How to track smart money flows in Vir Biotechnology Inc.2025 Market Trends & Low Drawdown Investment Ideas - Newser
Will a bounce in Vir Biotechnology Inc. offer an exitWall Street Watch & Low Drawdown Investment Ideas - Newser
Will earnings trigger a reversal in Vir Biotechnology Inc.July 2025 Snapshot & Safe Capital Investment Plans - Newser
Technical Models Detect Momentum Build in Vir Biotechnology Inc.July 2025 WrapUp & Long Hold Capital Preservation Tips - 선데이타임즈
Why Vir Biotechnology Inc. stock attracts strong analyst attentionGold Moves & Detailed Earnings Play Alerts - Newser
VIR Biotechnology’s SWOT analysis: stock outlook amid clinical trials and cash reserves - Investing.com
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - MSN
When is the best time to buy Vir Biotechnology Inc. stockReal-Time Entry Signals for Top Stocks - Newser
What is Vir Biotechnology Inc. s revenue forecastMassive Potential Swing Trades - kangso.co.kr
Vir Biotechnology’s Q2 2025: Unraveling Contradictions in ECLIPSE Trials, HDV Prevalence, and T-Cell Strategies - AInvest
Vir Biotechnology’s Earnings Call Highlights Progress and Challenges - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR) - The Globe and Mail
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $12 to $31 - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript - Insider Monkey
Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% After Earnings Miss - Defense World
Vir Biotechnology (VIR.O) Plunges 14.5%: What’s Driving the Intraday Swoon? - AInvest
Vir Biotechnology's 12.4% Intraday Drop: A Technical and Order-Flow Deep Dive - AInvest
Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips - Investing.com
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - BioSpace
Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum - MSN
Vir Biotechnology 2025 Q2 Earnings Losses Narrow 19.8% as Net Income Declines - AInvest
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Vir Biotechnology Reports Q2 2025 Financial Results - TipRanks
Vir Biotechnology's Q2 2025 Performance and Future Outlook: A Contrarian's Playbook for a Biotech Underdog - AInvest
Vir Biotechnology: A High-Conviction Play in Hepatitis Delta and Next-Gen Oncology Innovation - AInvest
Transcript : Vir Biotechnology, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Vir Biotechnology Q2 Earnings Fall Short of Estimates, Revenue Lags Behind - AInvest
Vir Biotechnology Q2 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. SEC 10-Q Report - TradingView
Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss - MarketScreener
Vir Biotechnology Q2 revenue misses expectations, net loss narrows - MarketScreener
Vir Biotechnology reports Q2 EPS (80c), consensus (72c) - TipRanks
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Vir Biotechnology enrolls first participant in ECLIPSE 3 trial - TipRanks
Vir Biotechnology successfully initiates all trials in Eclipse registrational program - MarketScreener
Vir Biotechnology completes initiation of hepatitis delta program By Investing.com - Investing.com Nigeria
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial - StreetInsider
Influenza A Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Cidara Therapeutics, Sab Biotherapeutics, Flugen, Moderna, Vir Biotechnology, Vaxart - Menafn
Vir Biotechnology Director SATO VICKI L Sells 22000 Shares at $4.99/Share. - AInvest
How strong is Vir Biotechnology Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Is Vir Biotechnology Inc. a good long term investmentMaximize gains with data-driven stock picks - Jammu Links News
Vir Biotechnology initiates second pivotal trial in its global ECLIPSE registrational program for chronic hepatitis delta - European AIDS Treatment Group
Is Vir Biotechnology Inc. stock overvalued or undervaluedMaximize your returns with expert insights - Jammu Links News
1.34%
0.52%
大文字化:
|
ボリューム (24 時間):